<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Sarcoma</journal-id><journal-title>Sarcoma</journal-title><issn pub-type="ppub">1357-714X</issn><issn pub-type="epub">1369-1643</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18521295</article-id><article-id pub-id-type="pmc">2395444</article-id>
            <article-id pub-id-type="pii">S1357714X00000219</article-id>
            <article-id pub-id-type="doi">10.1080/13577140020025869</article-id>
      <article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Intensified Adjuvant IFADIC Chemotherapy for Adult Soft Tissue
Sarcoma: A Prospective Randomized Feasibility Trial</article-title></title-group><contrib-group>
            <contrib contrib-type="author"><name><surname>Brodowicz</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib>
            <contrib contrib-type="author"><name><surname>Schwameis</surname><given-names>Eva</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib>
            <contrib contrib-type="author"><name><surname>Widder</surname><given-names>Joachim</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib>
            <contrib contrib-type="author"><name><surname>Amann</surname><given-names>Gabriele</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib>
            <contrib contrib-type="author"><name><surname>Wiltschke</surname><given-names>Christoph</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib>
            <contrib contrib-type="author"><name><surname>Dominkus</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib>
            <contrib contrib-type="author"><name><surname>Windhager</surname><given-names>Reinhard</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib>
            <contrib contrib-type="author"><name><surname>Ritschl</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib>
            <contrib contrib-type="author"><name><surname>P&#x000f6;tter</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib>
            <contrib contrib-type="author"><name><surname>Kotz</surname><given-names>Rainer</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib>
            <contrib contrib-type="author" corresp="yes"><name><surname>Zielinski</surname><given-names>Christoph C.</given-names></name><address><email>christoph.zielinski@akh-wien.ac.at</email></address><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff6">6</xref></contrib>
      </contrib-group>
            <aff id="aff1"><label>1</label>
                <addr-line>Clinical Division of Oncology</addr-line>
                <addr-line>Vienna</addr-line>
                <country>Austria</country>
            </aff>
            <aff id="aff2"><label>2</label>
                <addr-line>Department of Orthopedic Surgery</addr-line>
                <addr-line>Vienna</addr-line>
                <country>Austria</country>
            </aff>
            <aff id="aff3"><label>3</label>
                <addr-line>Department of Radiotherapy and Radiobiology</addr-line>
                <addr-line>Vienna</addr-line>
                <country>Austria</country>
            </aff>
            <aff id="aff4"><label>4</label>
                <addr-line>Department of Clinical Pathology</addr-line>
                <addr-line>University Hospital</addr-line>
                <addr-line>Vienna</addr-line>
                <country>Austria</country>
            </aff>
            <aff id="aff5"><label>5</label>
                <addr-line>Department of Orthopedic Surgery</addr-line>
                <addr-line>Orthopedic Hospital Gersthof</addr-line>
                <addr-line>Vienna</addr-line>
                <country>Austria</country>
            </aff>
            <aff id="aff6"><label>6</label>
                <addr-line>Medical Experimental Oncology and Ludwig Boltzmann Institute for Clinical Experimental Oncology</addr-line>
                <addr-line>Department of Medicine I</addr-line>
                <addr-line>University Hospital</addr-line>
                <addr-line>18-20 Waehringer Guertel</addr-line>
                <addr-line>Vienna</addr-line>
                <addr-line>A-1090</addr-line>
                <country>Austria</country>
            </aff>
        <pub-date pub-type="ppub"><month>12</month><year>2000</year></pub-date><volume>4</volume><issue>4</issue><fpage>151</fpage><lpage>160</lpage><permissions><copyright-statement>Copyright &#x000a9; 2000 Hindawi Publishing Corporation.</copyright-statement><copyright-year>2000</copyright-year><copyright-holder>Hindawi Publishing Corporation</copyright-holder><license license-type="open-access" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract>
            <p><italic>Purpose.</italic> The present prospective randomized adjuvant trial was
            carried out to compare the toxicity, feasibility and efficacy of augmented chemotherapy
            added to hyperfractionated accelerated radiotherapy after wide or marginal resection of grade
            2 and grade 3 soft tissue sarcoma (STS).</p>
            <p><italic>Patients and methods. </italic> Fifty-nine patients underwent primary surgery
            by wide or marginal excision and were subsequently randomized to receive radiotherapy
            alone or under the addition of six courses of ifosfamide (1500 mg/m<sup>2</sup>
, days 1&#x02013;4), dacarbazine
              (DTIC) (200 mg/m<sup>2</sup>
, days 1&#x02013;4) and doxorubicin (25 mg/m<sup>2</sup>
, days 1&#x02013;2) administered in
              14-day-intervals supported by granulocyte-colony stimulating factor (30 &#x000d7; 10<sup>6</sup>
 IU/day, s.c.)
              on days 5&#x02013;13. According to the randomization protocol, 28 patients received radiotherapy
              only, whereas 31 patients were treated with additional chemotherapy.</p>
              <p><italic>Results.</italic> The relative ifosfamide&#x02013;doxorubicin&#x02013;DTIC (IFADIC) dose
              intensity achieved was 93%. After a mean observation period of 41&#x000b1;19.7 months
              (range, 8.1&#x02013;84 months), 16 patients (57%) in the control group versus 24 patients (77%) in the
             chemotherapy group were free of disease (p&#x0003e;0.05).Within the control group, tumor relapses
             occurred in 12 patients (43%;six patients with distant metastases, two with local relapse,
             four with both) versus seven patients (23%; five patients with distant metastases, one with
             local recurrence, one with both) from the chemotherapy group. Relapse-free survival (RFS)
            (<italic>p</italic>=0.1), time to local failure (TLF) (<italic>p</italic>=0.09), time to distant failure (TDF) (<italic>p</italic>=0.17) as well as
            overall survival (OS) (<italic>p</italic>=0.4) did not differ significantly between the two treatment groups.
            Treatment-related toxicity was generally mild in both treatment arms.</p>
            <p><italic>Conclusion.</italic> We conclude that the safety profile of intensified IFADIC
            added to radiotherapy was manageable and tolerable in the current setting. Inclusion
            of intensified IFADIC was not translated into a significant benefit concerning OS, RFS,
          TLF andTDF as compared with radiotherapy only, although a potential benefit of
          chemotherapy for grade 3 STS patients needs to be validated in prospective randomized
          trials including larger patient numbers.</p>
        </abstract></article-meta></front></article>


